专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080188663A1 Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I 审中-公开
标题翻译：结晶氯吡格雷硫酸氢盐的制备方法I型
公开(公告)号：US20080188663A1
公开(公告)日：2008-08-07
申请号：US12010581
申请日：2008-01-28
申请人： Ashok Kumar , Priti J. Bhayani , Vaibhav Chinubhai Doshi , Ashvini Saxena , Gunjan Pramod Pathak , Rashmi Abhyankar , Sarvanan Manavalan , Mukesh Purohit
发明人： Ashok Kumar , Priti J. Bhayani , Vaibhav Chinubhai Doshi , Ashvini Saxena , Gunjan Pramod Pathak , Rashmi Abhyankar , Sarvanan Manavalan , Mukesh Purohit
IPC分类号： C07D221/04
CPC分类号： C07D495/04
摘要： The present invention describes an improved industrial process for crystallizing polymorph Form I of (+) clopidogrel hydrogen sulphate (also called clopidogrel bisulphate) in either a Type-I solvent or a Type-II. Type I solvent is an organic solvent containing two or more functional groups with a proviso that at least one functional group is different from the other(s). The Type II solvent is selected from methyl ethyl ketone, cyclopentylmethyl ether, dipropylglycolether, dibutylglycol ether, propylmethyl cellosolve, butylmethylcellosolve, propylethylellosolve, butylethylcellosolve or their cross combinations. The process produces Form I in a reproducible manner without detectable contamination of polymorph designated as Form II.
摘要翻译：本发明描述了在I型溶剂或II型中结晶（+）氯吡格雷硫酸氢盐（也称为氯吡格雷硫酸氢盐）的多晶型物I的改进的工业方法。 I型溶剂是含有两个或更多个官能团的有机溶剂，条件是至少一个官能团与另一个官能团不同。 II型溶剂选自甲基乙基酮，环戊基甲基醚，二丙基乙二醇醚，二丁基乙二醇醚，丙基甲基溶纤剂，丁基甲基溶纤剂，丙基乙醚基醚，丁基乙基溶纤剂或它们的交叉组合。该方法以可再现的方式产生I型，而不检测到指定为II型的多晶型物质的污染。

2. 发明授权

US07470816B2 Tramadol recovery process 失效
标题翻译：曲马多恢复过程
公开(公告)号：US07470816B2
公开(公告)日：2008-12-30
申请号：US11598472
申请日：2006-11-13
申请人： Ashok Kumar , Suneel Yeshwant Dike , Satish Rajanikant Soudagar , Chirag Hasmukh Shah , Sandeep Madhavrao Burudkar , Prashant Gautam , Byju Nellithanath Thankachen , Ashvini Saxena , Manavalan Saravanan , Gunjan Pramod Pathak , Virendra Pal , Rahul Karde , Jaysingh Gehlot
发明人： Ashok Kumar , Suneel Yeshwant Dike , Satish Rajanikant Soudagar , Chirag Hasmukh Shah , Sandeep Madhavrao Burudkar , Prashant Gautam , Byju Nellithanath Thankachen , Ashvini Saxena , Manavalan Saravanan , Gunjan Pramod Pathak , Virendra Pal , Rahul Karde , Jaysingh Gehlot
IPC分类号： C07B57/00 , C07C211/16
CPC分类号： C07C213/10 , C07C2601/14 , C07C217/74
摘要： A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.
摘要翻译：一种用于拆分异构的曲马多混合物的方法，包括：提供包含顺式和反式曲马多的纯化原料; 在有效形成纯化原料中顺式和反式反胺氨肟酸盐的条件下，使纯化原料与酸接触; 并将顺式 - 曲马多酸盐与反式 - 马来丙醇分离，得到纯化的顺 - 曲马多酸盐; 并且任选地将顺式 - 曲马多酸盐转化成顺式 - 曲马多或其药物活性盐。

3. 发明申请

US20080261959A1 Novel crystalline forms of (S)-N-(1-Carboxy-2-methyl-prop-1-y)-N-pentanoyl-N[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine 审中-公开
标题翻译：（S）-N-（1-羧基-2-甲基 - 丙-1-基）-N-戊酰基-N [2' - （1H-四唑-5-基）双苯基-4- 吡啶-2-基甲基] - 胺
公开(公告)号：US20080261959A1
公开(公告)日：2008-10-23
申请号：US11984717
申请日：2007-11-21
申请人： Ashok Kumar , Manmohan Madhavrao Nimbalkar , Priti Jayesh Bhayani , Mukesh Subhodh Jha , Vaibhav Chinubhai Doshi
发明人： Ashok Kumar , Manmohan Madhavrao Nimbalkar , Priti Jayesh Bhayani , Mukesh Subhodh Jha , Vaibhav Chinubhai Doshi
IPC分类号： A61K31/41 , C07D257/04 , A61K31/549 , A61K31/4422 , A61P9/12
CPC分类号： C07D257/04
摘要： This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and in this connection, to the amorphous form of valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of valsartan.
摘要翻译：本发明涉及缬沙坦的新型结晶形式，即A型，B型，C型，D型及其溶剂合物。还提供了用于制备新颖形式的方法。本发明还涉及用于制备稳定的无定形形式的缬沙坦的新方法，并且在这方面，涉及通过这些方法产生的无定形形式的缬沙坦。本发明还公开了获得稳定的缬沙坦I型晶体的新方法。

4. 发明申请

US20070027202A1 Process for the preparation of carvedilol and its salts 审中-公开
标题翻译：卡维地洛及其盐的制备方法
公开(公告)号：US20070027202A1
公开(公告)日：2007-02-01
申请号：US11480526
申请日：2006-07-05
申请人： Ashok Kumar , Ashvini Saxena , Anindya Battacharyya , Amit Sengar , Gunjan Pathak , Satish Soudagar , Pramil Mathur , Avinash Nijasure , Sanjukumar Salunke , Prashant Gautam , Thakur Ramsingh , Dilip Jadhav
发明人： Ashok Kumar , Ashvini Saxena , Anindya Battacharyya , Amit Sengar , Gunjan Pathak , Satish Soudagar , Pramil Mathur , Avinash Nijasure , Sanjukumar Salunke , Prashant Gautam , Thakur Ramsingh , Dilip Jadhav
IPC分类号： C07D209/82 , A61K31/403
CPC分类号： C07D209/88
摘要： Disclosed herein is a process for preparation of carvedilol substantially free from its bis-impurity comprises the reaction of 4-(2,3-epoxypropoxy)carbazole and 2-(2-methoxyphenoxy)ethylamine in a polar aprotic solvent media; followed by isolation of carvediol from the reaction mass as an acid addition salt and subsequent conversion into pure carvedilol.
摘要翻译：本文公开了一种制备基本上不含其双杂质的卡维地洛的方法，包括4-（2,3-环氧丙氧基）咔唑和2-（2-甲氧基苯氧基）乙胺在极性非质子溶剂介质中的反应; 然后将其作为酸加成盐从反应物料中分离出来，随后转化为纯的卡维地洛。

5. 发明申请

US20070112074A1 Tramadol recovery process 失效
标题翻译：曲马多恢复过程
公开(公告)号：US20070112074A1
公开(公告)日：2007-05-17
申请号：US11598472
申请日：2006-11-13
申请人： Ashok Kumar , Suneel Dike , Satish Soudagar , Chirag Shah , Sandeep Burudkar , Prashant Gautam , Byju Thankachen , Ashvini Saxena , Manavalan Saravanan , Gunjan Pathak , Virendra Pal , Rahul Karde , Jaysingh Gehlot
发明人： Ashok Kumar , Suneel Dike , Satish Soudagar , Chirag Shah , Sandeep Burudkar , Prashant Gautam , Byju Thankachen , Ashvini Saxena , Manavalan Saravanan , Gunjan Pathak , Virendra Pal , Rahul Karde , Jaysingh Gehlot
IPC分类号： A61K31/137 , C07C213/10
CPC分类号： C07C213/10 , C07C2601/14 , C07C217/74
摘要： A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.
摘要翻译：一种用于拆分异构的曲马多混合物的方法，包括：提供包含顺式和反式曲马多的纯化原料; 在有效形成纯化原料中顺式和反式反胺氨肟酸盐的条件下，使纯化原料与酸接触; 并将顺式 - 曲马多酸盐与反式 - 马来丙醇分离，得到纯化的顺 - 曲马多酸盐; 并且任选地将顺式 - 曲马多酸盐转化成顺式 - 曲马多或其药物活性盐。

6. 发明申请

US20070255056A1 Method for manufacture of compounds related to the class of substituted sulfonyl urea anti-diabetics 审中-公开
标题翻译：制备与取代的磺酰脲类抗糖尿病药类有关的化合物的方法
公开(公告)号：US20070255056A1
公开(公告)日：2007-11-01
申请号：US11371911
申请日：2006-03-10
申请人： Ashok Kumar , Satish Soudagar , Pramil Mathur , Arpana Mathur , Dadaso Dalavi , Sanjay Gunjal , Uttamrao Sawant , Ashvini Saxena , Bimal Srivastava , Praveen Singh , Jagdish Sankla , Vijay Dhurandhare
发明人： Ashok Kumar , Satish Soudagar , Pramil Mathur , Arpana Mathur , Dadaso Dalavi , Sanjay Gunjal , Uttamrao Sawant , Ashvini Saxena , Bimal Srivastava , Praveen Singh , Jagdish Sankla , Vijay Dhurandhare
IPC分类号： C07C311/21 , C07D207/24 , C07D209/52 , C07D223/04 , C07D295/14 , C07D413/12
CPC分类号： C07D241/24 , C07C303/40 , C07D207/38 , C07D263/34 , C07C311/59
摘要： The present invention relates to a process for preparation of sulfonyl urea compounds in high conversion rates and purity. More specifically, this invention relates to a process for manufacture of sulfonyl urea class of anti-diabetic pharmaceutical drugs in higher purity and yield. The process may effectively and economically be used to produce anti-diabetic drugs, such as glimepiride, glipizide, gliclazide, glibenclamide, glibornuride, and glisoxepide.
摘要翻译：本发明涉及以高转化率和纯度制备磺酰脲化合物的方法。更具体地，本发明涉及以更高的纯度和产率制造磺酰脲类抗糖尿病药物的方法。该方法可以有效和经济地用于产生抗糖尿病药物，例如格列美脲，格列吡嗪，格列齐特，格列本脲，格列本脲和格列霉素。

7. 发明授权

US09345773B2 PVA-boronic acid containing copolymer compositions for protein delivery 有权
标题翻译：含有PVA-硼酸的蛋白质递送共聚物组合物
公开(公告)号：US09345773B2
公开(公告)日：2016-05-24
申请号：US13880299
申请日：2011-08-08
申请人： Ashok Kumar , Rachamalla Maheedhar Reddy
发明人： Ashok Kumar , Rachamalla Maheedhar Reddy
IPC分类号： A61K47/32 , A61K9/50 , A61K9/51 , A61K31/78 , C08F220/56 , C08L33/24
CPC分类号： A61K47/32 , A61K9/5026 , A61K9/5138 , A61K31/78 , C08F220/56 , C08L33/24 , C08F220/54 , C08F220/34 , C08L29/04
摘要： Provided herein are phenylboronate containing co-polymers (PCC), compositions containing PCC and polyvinyl alcohol (PVA), such compositions further including proteins, methods of making these compositions by water in oil polymerization, and methods of using the protein containing compositions for releasing proteins. Such phenylboronate containing co-polymers are of Formula I: where m, n, p, x, R1-R5, L, X1 and X2 are defined in the application.
摘要翻译：本文提供含苯基硼酸盐的共聚物（PCC），含有PCC和聚乙烯醇（PVA）的组合物，此类组合物还包括蛋白质，通过水中油聚合制备这些组合物的方法，以及使用含蛋白质组合物释放蛋白质的方法。这种苯基硼酸酯的共聚物具有式I：其中m，n，p，x，R 1 -R 5，L，X 1和X 2在本申请中定义。

8. 发明授权

US08916343B2 DNA biochip and methods of use 有权
标题翻译： DNA生物芯片和使用方法
公开(公告)号：US08916343B2
公开(公告)日：2014-12-23
申请号：US12931116
申请日：2011-01-24
申请人： Arun Kumar , Ashok Kumar , Shree R. Singh , Souheil Zekri
发明人： Arun Kumar , Ashok Kumar , Shree R. Singh , Souheil Zekri
IPC分类号： C12Q1/68 , C12M1/36 , G01N15/06 , C07H21/04 , G01N33/569 , G01N33/53
CPC分类号： G01N33/56983 , C12Q1/6825 , C12Q1/6837 , G01N33/5308 , C12Q2527/125 , C12Q2565/501 , C12Q2565/607
摘要： The subject invention concerns materials and methods for detecting nucleic acid sequences. One aspect of the invention concerns a silicon-based “biochip” comprising nucleic acid immobilized thereon. In one embodiment, the silicon comprises microcavities. The nucleic acid to be assayed for the presence of one or more target nucleic acid sequences is immobilized on the silicon. A nucleic acid, such as an oligonucleotide probe, having a sequence substantially complementary to the target nucleic acid sequence can be used to detect the immobilized nucleic acid on the silicon. If the nucleic acid used for detection hybridizes with a target nucleic acid sequence, the hybridized sequences can be detected directly or indirectly. In an exemplified embodiment, the oligonucleotide probe can be labeled with a detectable label, for example, a fluorescent molecule. The subject invention also concerns methods for detecting a target nucleic acid using a silicon-based biochip of the invention.
摘要翻译：本发明涉及用于检测核酸序列的材料和方法。本发明的一个方面涉及包含固定在其上的核酸的硅基“生物芯片”。在一个实施例中，硅包括微腔。要测定的一种或多种靶核酸序列的存在的核酸被固定在硅上。可以使用具有与靶核酸序列基本上互补的序列的核酸，例如寡核苷酸探针，以检测硅上的固定化核酸。如果用于检测的核酸与靶核酸序列杂交，则可以直接或间接检测杂交的序列。在示例性实施方案中，寡核苷酸探针可以用可检测标记，例如荧光分子标记。本发明还涉及使用本发明的硅基生物芯片检测靶核酸的方法。

9. 发明授权

US08668938B2 Composition and manufacturing processes of a toxicity free botanical drug for curative treatment of chronic diseases 有权
标题翻译：无毒性植物药物用于治疗慢性疾病的组成和制造过程
公开(公告)号：US08668938B2
公开(公告)日：2014-03-11
申请号：US13575807
申请日：2010-01-29
申请人： Ashok Kumar , Aditi Kumar , Prakrati Kumar , Priti Kumar
发明人： Ashok Kumar , Aditi Kumar , Prakrati Kumar , Priti Kumar
IPC分类号： A01N65/00
CPC分类号： A61K36/23 , A61K36/88 , A61K2300/00
摘要： This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants Crinum asiaticum and Crocus sativus. This drug was administered to human volunteers by oral and intranasal routes in effective amount for an effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease. In vitro experiments show that this botanical drug causes proliferation and differentiation of stem cells.
摘要翻译：本发明公开了用于治疗慢性疾病的无毒性植物药物制剂的组合物和制造方法。它由植物Crinum asiaticum和Crocus sativus制成。该药物通过口服和鼻内途径以有效的时间段施用于人类志愿者。根据年龄，体重，疾病长度，疾病的严重程度，疾病的类型，有效量和有效的给药时间因人类志愿者而异。体外实验表明，这种植物药物引起干细胞的增殖和分化。

10. 发明申请

US20130179833A1 APPLICATION SHORTCUT USER INTERFACE SYSTEMS AND METHODS 有权
标题翻译：应用更快的用户界面系统和方法
公开(公告)号：US20130179833A1
公开(公告)日：2013-07-11
申请号：US13343909
申请日：2012-01-05
申请人： Heath Stallings , Omar Abou-Khamis , Nathan J. Maxfield , Ashok Kumar , Andrien J. Wang , Don G. Archer , Aravind Perumandla
发明人： Heath Stallings , Omar Abou-Khamis , Nathan J. Maxfield , Ashok Kumar , Andrien J. Wang , Don G. Archer , Aravind Perumandla
IPC分类号： G06F3/048
CPC分类号： G06F3/0482
摘要： An exemplary method includes a user computing device 1) determining current states, such as current integration states and/or current operational states, of software applications included in a suite of software applications relative to the user computing device, 2) identifying, based on the current states, access options for the software applications included in the suite of software applications, and 3) providing, by the user computing device for display, a graphical user interface that includes the access options configured to be selected by a user of the user computing device to access the software applications included in the suite of software applications. Corresponding methods and systems are also disclosed.
摘要翻译：一种示例性方法包括用户计算设备1）确定包括在相对于用户计算设备的软件应用套件中的软件应用的当前状态，例如当前集成状态和/或当前操作状态，2）基于当前状态，软件应用程序包括的软件应用程序的访问选项，以及3）由用户计算设备提供用于显示的图形用户界面，其包括被配置为由用户计算的用户选择的访问选项设备访问软件应用程序套件中包含的软件应用程序。还公开了相应的方法和系统。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式